Skip to main content
Premium Trial:

Request an Annual Quote

Quanterix Q2 Revenues Rise 32 Percent

NEW YORK – Quanterix on Tuesday reported a 32 percent rise in second quarter 2023 revenues.

For the three months ended June 30, the company reported revenue of $31.0 million, up from $23.5 million in Q2 2022 and beating the consensus Wall Street estimate of $25.9 million.

In a statement accompanying release of the earnings results, Quanterix President and CEO Masoud Toloue said that the corporate restructuring the company launched roughly a year ago was "accelerating progress as evidenced by both financial and business results."

Quanterix's Q2 product revenues were up 33 percent to $19.7 million from $14.8 million in Q2 2022. Service and other revenues were up 25 percent to $10.6 million from $8.5 million in the prior-year period. Collaboration and license revenue was up nearly sevenfold to $629,000 from $92,000 in Q2 2022. Grant revenue more than doubled to $156,000 from $75,000 in the prior-year period.

The Q2 revenue figures include a one-time benefit of roughly $1.5 million related to product and license agreements.

Quanterix's Q2 net loss was $6.1 million, or $.16 per share, versus $24.9 million, or $.67 per share, a year ago. Analysts, on average, had predicted a net loss of $.38 per share.

Quanterix's R&D spending during the quarter was down 11 percent to $5.9 million from $6.6 million in Q2 2022, and its SG&A expenses fell 20 percent to $21.6 million from $27.0 million a year ago.

It raised its full-year 2023 revenue guidance to between $110 million and $116 million from previous guidance of $104 million to $111 million.

Quanterix ended the quarter with $329.5 million in cash and cash equivalents and $2.7 million in restricted cash.

In Tuesday morning trading on Nasdaq, Quanterix stock was up 21 percent to $26.21.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.